Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients ’ quality of life...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Kazumi Sano, Kazuhiko Nakadate and Kazuhiko Hanada Tags: Research article Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Minocycline | Non-Small Cell Lung Cancer | Skin | Solodyn